Dipentum Alternatives Compared
| Dipentum | Entyvio | Simponi |
|
|---|
| Dipentum (olsalazine) | Entyvio (vedolizumab) | Simponi (golimumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Ulcerative Colitis - Active, Ulcerative Colitis - Maintenance, Ankylosing Spondylitis, Ulcerative Colitis. Dipentum may also be used for purposes not listed in this medication guide. |
Prescription only
Entyvio is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically instead of... View more |
Prescription only
Prescribed for Rheumatoid Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Psoriatic Arthritis, Spondyloarthritis. Simponi may also be used for purposes not listed in this medication guide. |
Related suggestions Ulcerative Colitis
|
|||||||||||||||||||||||
| More about Dipentum (olsalazine) | More about Entyvio (vedolizumab) | More about Simponi (golimumab) | ||||||||||||||||||||||||
| Generic Status | ||||||||||||||||||||||||||
|
No lower-cost generic available |
No lower-cost generic available |
No lower-cost generic available |
||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Dipentum has an average rating of 9.7 out of 10 from a total of 4 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Entyvio has an average rating of 6.0 out of 10 from a total of 145 ratings on Drugs.com. 46% of reviewers reported a positive effect, while 30% reported a negative effect. |
Simponi has an average rating of 6.3 out of 10 from a total of 114 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 30% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
See also: Dipentum side effects in more detail. |
See also: Entyvio side effects in more detail. |
See also: Simponi side effects in more detail. |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Dipentum prices |
View all Entyvio prices |
View all Simponi prices |
||||||||||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
Other golimumab brands include: Simponi Aria | ||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
55 hours |
600 hours |
336 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 118 drugs are known to interact with Dipentum:
|
A total of 149 drugs are known to interact with Entyvio:
|
A total of 466 drugs are known to interact with Simponi:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
July 31, 1990 |
May 20, 2014 |
April 24, 2009 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.